Ram Rapur, Guditi Swarnalatha, Kaligotla Venkata Dakshinamurty
Department of Nephrology, Sri Venkateswara Institute of Medical Sciences , Tirupati, Andhra Pradesh , India and.
Ren Fail. 2015 Apr;37(3):452-5. doi: 10.3109/0886022X.2014.996731. Epub 2015 Jan 16.
The studies of idiopathic membranous nephropathy (IMN) require sufficiently long duration of follow-up to understand the effect of treatment on the development of end-stage renal disease (ESRD) in IMN. The aim was to assess the remission rates with steroids and cyclophosphamide regimen for IMN at the end of 10 years of follow-up. A prospective, open-label study performed in Nephrology department of a state run tertiary care centre in a southern state of India. Adult (age >18 years) patients with biopsy-proven IMN of at least 6-month duration were included in the study. Patients received a 6-month course of alternate months of steroid and cyclophosphamide. The patients were followed for 10 years. Study end points were doubling of serum creatinine, development of ESRD, or death. A total of 58 IMN patients were recruited from 1997 to 2001. Out of 58 patients included, only 48 patients could complete the treatment schedule in six months. The remission rate at the end of 10 years was 58.6% (34 in 58 patients). The probability of dialysis-free survival in our study was 89.6% at the end of 10 years follow-up. The regimen of steroids and cyclophosphamide in IMN had a remission rates not as high as reported before. It was associated with high relapse rates and more infections.
对特发性膜性肾病(IMN)的研究需要足够长的随访时间,以了解治疗对IMN患者终末期肾病(ESRD)发展的影响。本研究旨在评估在随访10年末,使用类固醇和环磷酰胺方案治疗IMN的缓解率。这是一项在印度南部一个邦的国立三级医疗中心肾内科进行的前瞻性、开放标签研究。研究纳入了年龄大于18岁、经活检证实患有IMN且病程至少6个月的成年患者。患者接受为期6个月的类固醇和环磷酰胺交替治疗疗程。对患者进行了10年的随访。研究终点为血清肌酐翻倍、ESRD的发生或死亡。1997年至2001年共招募了58例IMN患者。在纳入的58例患者中,只有48例患者能够在6个月内完成治疗方案。10年末的缓解率为58.6%(58例患者中有34例缓解)。在10年随访结束时,我们研究中无透析生存的概率为89.6%。IMN患者使用类固醇和环磷酰胺方案的缓解率不如之前报道的高。它与高复发率和更多感染相关。